Exploratory study of CIGB-300 treatment in refractory or relapsing acute leukemias, elderly acute myeloid leukemia and myelodysplastic syndrome with excess blasts. - EHPMA Study
Latest Information Update: 14 Oct 2020
At a glance
- Drugs CIGB 300 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms EHPMA
- 29 Aug 2016 New trial record